Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial complementarity to the shRNA guide strand represent a significant challenge in RNA interference (RNAi) technology, where short hairpin RNAs (shRNAs) inadvertently silence genes other than the intended target. This phenomenon primarily occurs through a microRNA-like mechanism, where the 'seed region' (nucleotides 2-8) of the shRNA guide strand binds to the 3' untranslated region (UTR) of unintended transcripts (Jackson et al., 2003; Birmingham et al., 2006). Such interactions can lead to widespread changes in the cellular transcriptome, potentially causing false-positive results in functional genomics research or severe toxicity in clinical applications. In therapeutic contexts, high levels of shRNA expression can also saturate the endogenous RNAi machinery, such as Exportin-5 and the RNA-induced silencing complex (RISC), interfering with natural microRNA processing and leading to organ failure or death (Grimm et al., 2006). Strategies to mitigate these effects include optimized sequence design to avoid common seed sequences, chemical modifications of the guide strand, and the use of inducible or tissue-specific promoters to limit shRNA concentration (Sigoillot et al., 2012). Understanding and predicting these off-target interactions is critical for the development of safe and effective RNAi-based therapeutics.
RNA interference (RNAi) pathway mediated by the RNA-induced silencing complex (RISC), where the guide strand binds to partially complementary sequences (typically in the 3' UTR) of unintended mRNAs, leading to translational repression or mRNA degradation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to the shRNA guide strand (shRNA off-targets).